Aug 9
|
Solid Earnings Reflect AstraZeneca's (LON:AZN) Strength As A Business
|
Aug 7
|
Influenza Vaccine Market Research Report 2025-2030 Featuring GSK, Abbott, Pfizer, AstraZeneca, Sanofi, Moderna, CSL, Emergent BioSolutions, BIKEN, Serum Institute of India, Sinovac, GC Biopharma
|
Aug 7
|
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) and adults with generalized myasthenia gravis (gMG)
|
Aug 7
|
RFK Jr’s mRNA funding halt signals “shift in US public health”
|
Aug 7
|
Inside AstraZeneca’s long-game strategy in lung cancer
|
Aug 6
|
IonQ Announces Second Quarter Financial Results
|
Aug 6
|
Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update
|
Aug 6
|
Compugen Reports Second Quarter 2025 Results
|
Aug 6
|
US Health Department Ending Federal mRNA Vaccine Development
|
Aug 6
|
Cancer Antibody Drug Conjugates Market Research 2025-2031 | Pfizer, AstraZeneca, and Biotechs Like Miracogen Advance Cancer ADCs with Strategic Acquisitions and Innovative Pipelines
|
Aug 6
|
Trump says pharma tariffs to start small, then soar to 250%
|
Aug 5
|
Trump threatens 250pc tariffs on drug imports
|
Aug 5
|
EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data
|
Aug 5
|
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
|
Aug 4
|
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates
|
Aug 4
|
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
|
Aug 4
|
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval
|
Aug 3
|
Why Drug Prices for Some Big Medicines Will Remain High for a Longer Time
|
Aug 2
|
Drugmakers are pouring billions of dollars into new US manufacturing. It still won’t achieve all of Trump’s tariff goals
|
Aug 2
|
AstraZeneca Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
|